The mammalian target of rapamycin (mTOR) kinase integrates cues from nutrients and growth factors, acting as a nexus point for cellular signals to control growth, metabolism, and longevity. Deregulation of either of mTOR's two complexes, mTORC1 or mTORC2, leads to diseases of metabolism, including cancer and diabetes. In this issue's Select, insights into the extent of mTOR's oncogenic capabilities come to light, and it appears that an old drug (rapamycin) has some new tricks in vivo.
mTOR's Translational Landscape in Sickness and in Health
One of mTOR's key roles is to regulate protein synthesis. But identifying the full repertoire of mTOR's translational targets has been difficult, partly because rapamycin, the most widely used mTOR inhibitor, does not inhibit all mTOR functions. A class of nextgeneration ATP site mTOR inhibitors in combination with a powerful new technique, ribosome profiling, is used in two recent studies to great effect. Thoreen et al. (2012) use transcriptome-wide profiling in mouse embryonic fibroblasts to define the translational program in a normal 'healthy' setting, and Hsieh et al. (2012) interrogate the translational networks of a prostate cancer genome in the context of oncogenic mTOR hyperactivation. Thoreen et al. identify a unifying 5 0 terminal oligopyrimidine (TOP) or related (TOP-like) motif in nearly all transcripts specifically regulated by mTORC1 (including a class of transcripts that had not previously been known as TOP mRNAs), but they find no evidence for a previously postulated theory that mTORC1 regulates the translation of mRNAs with highly structured and complex 5 0 untranslated regions (5 0 UTR). Hsieh et al. uncover a new cis-regulatory element within the 5 0 UTR of mTOR-sensitive mRNAs termed the pyrimidine-rich translational element (PRTE). The mechanism of action that renders TOP, TOP-like, and PRTE-containing transcripts sensitive to mTORC1 regulation is reliant on the inhibitory eIF4E-binding protein (4E-BP) family of translational repressors. Hsieh et al. focus their attention on prostate cancer, as mTOR is deregulated in almost all advanced human prostate cancers. They find that a specific set of genes, which cluster into specific nodes of gene expression important for cancer initiation and progression, is translationally downregulated upon inhibition of aberrant mTOR signaling. The authors identify and characterize a class of translationally regulated invasion genes, including CD44 and vimentin, each of which contains a PRTE. The authors go on to develop a clinical-grade ATP site inhibitor of mTOR, INK128, which effectively decreases the translation of the mTOR-regulated invasion signature and prevents prostate cancer cell invasion and metastasis in preclinical animal trials. Together, Hsieh et al. and Thoreen et al. demonstrate that the 4EBP/eIF4E axis plays important roles in both normal physiologic and oncogenic translational programs, so it will be important to understand how to differentially target the invasive program of cancerous cells without disrupting mTOR signaling in healthy tissue when developing therapeutic interventions. Hsieh, A.C., et al. (2012) . Nature 485, 55-61. Thoreen, C.C., et al. (2012) . Nature 485, [109] [110] [111] [112] [113] 
mTORC1 Activation Alone Can Cause Carcinomas in Mice
Though it is well established that mTOR signaling is often deregulated during cancer growth, it has been unclear whether the mTOR axis can itself act as a driver of tumorigenesis. A study from Menon et al. now provides evidence that simply upregulating mTORC1 activity by deleting TSC1 in the liver is sufficient to trigger spontaneous development of hepatocellular carcinomas in mice. TSC1 is an upstream inhibitor of mTORC1, and so in its absence, mTORC1 signaling is chronically increased. Before the onset of overt tumors, liver damage, inflammation, and regenerative proliferation are visible in the TSC1 liver knockout mice, and these features, as well as the tumors themselves, are prevented by treatment with the mTORC1 inhibitor rapamycin. ER stress and aberrant inhibition of autophagy are molecular consequences of chronic mTORC1 signaling and are both shown to be instrumental in the accumulated cellular damage in these liver cells. The increase in damaged organelles and the concomitant decrease in the ability of the cells to process and remove the damage create a tumorigenic environment predisposing the tissue to cancer. These results are Chronic mTORC1 activation in mice with liver-specific knockout of Tsc1 (LTsc1KO) causes a defect in autophagy, as indicated by increased p62 staining and aggregation (arrow), which contributes to liver damage and inflammatory cell infiltration (I). Image courtesy of B. Manning.
particularly concerning, as the increased mTORC1 activity and early liver damage seen in this experimental setting are reminiscent of the hepatic changes induced by obesity. This direct link between increased flux through the nutrient-sensing mTOR pathway and enhanced rate of carcinogenesis provides support for theories that couple diet to cancer risk. Menon, S., et al. (2012) . Sci. Signal. 5, ra24. A New Member of the Rag-time Band
The Ragulator-Rag GTPase complex recruits mTORC1 to the lysosomal membrane and is responsible for its ability to sense amino acid availability in the cell. Intriguing hints for how Rag GTPases sense amino acids are gradually coming into focus. Recent reports describe an interaction between Ragulator and a vacuolar ATPase allowing an easy access point to sample the amino acids in the lysosomal lumen; and an even more direct link to amino acid levels was demonstrated upon identification of leucyl-tRNA synthetase as a GAP for RagD. A study from Kim et al. (2012) now provides a further piece of the puzzle. The authors identify a protein named SH3BP4 that binds to inactive RagGTPase complex in leucine-deprived conditions. SH3BP4 inhibits mTORC1 signaling, suppressing cell growth and promoting autophagy. The SH3BP4 gene locus is deleted in human breast and renal cancers with a high frequency, providing another link between deregulated mTOR signaling and tumorigenesis. The interaction between SH3BP4 and Rag GTPases prevented mTORC1 its recruitment to the lysosome, though how the inhibitory complex interacts with Ragulator and other components of the amino-acid-sensing machinery is yet to be determined. As SH3BP4 is known to bind to dynamin, this link provides an intriguing glimpse at global coordination of endosomal trafficking and nutrient sensing at the lysosome. Kim, Y.M., et al. (2012) . Mol. Cell. Published online May 10, 2012 . 10.1016 /j.molcel.2012 .007.
Two Targets of Rapamycin
As the name indicates, one of the salient features of mTOR kinase action is that it is inhibited by the small molecule rapamycin. It has been long thought that only mTORC1 is targeted by rapamycin, inhibiting mTOR's action on growth, proliferation, and differentiation, whereas mTORC2, which signals through the insulin-signaling cascade, is not a pharmacologically relevant target of the drug. New data from Lamming et al. (2012) , however, question this notion. The authors first wanted to know why, when both caloric restriction (CR) and chronic rapamycin administration (i.e., mTORC1 inhibition) are known to increase life span in model organisms, the latter treatment reduces glucose tolerance and insulin action, which is the opposite physiological effect of CR. Through a series of elegant experiments, the authors show that mTORC1 inhibition alone cannot account for the changes in glucose homeostasis seen during rapamycin-induced life span increases in mice. Instead, disruption of mTORC2 signaling, evidenced by dissociation of Rictor from mTORC2 and subsequent decrease in phosphorylation of mTORC2 substrates, is essential for the effects of rapamycin on glucose tolerance. Genetic knockouts that impair mTORC1 function but leave mTORC2 signaling intact show increased life spans but with normal glucose tolerance and insulin sensitivity. These results suggest that the beneficial (life span extending) and detrimental (insulin insensitivity) effects of rapamycin can be uncoupled at the level of the mTOR complex that is targeted, highlighting the potential utility of specific mTORC1 inhibitors. Lamming, D.W., et al. (2012) . Science 335, 1638 Science 335, -1643 . Rapamycin was discovered in soil samples taken from Easter Island, or Rapa Nui in Polynesian; the drug was named accordingly.
